Overview

Preventing of GVHD with Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Ruxolitinib At Children and Young Adults with Hemoblastosis

Status:
RECRUITING

Trial end date:
2026-10-10

Target enrollment:

Participant gender:

Summary

GVHD prevention using a combination of post-transplantation cyclophosphamide in combination with abatacept, vedolizumab and Ruxolitinib in children and young adults with hematoloblastosis after myeloablative conditioning regimen with treosulfan/TBI, etoposide, fludarabine after HSCT from matched unrelated and haploidentical donors

Phase:

PHASE2

Details

Lead Sponsor:

Federal Research Institute of Pediatric Hematology, Oncology and Immunology

Treatments:

Etoposide